Fadi S. Braiteh
Oncology
3730 S Eastern Ave
Las Vegas, NV 89169
Las Vegas, NV 89169
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Journal: ESMO open
Published: October 03, 2025
Exploring decisional control preferences in older patients with cancer and their caregivers.
Journal: Journal of geriatric oncology
Published: October 31, 2024
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: January 08, 2024
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
Journal: ESMO open
Published: December 14, 2022
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Journal: Cancer
Published: October 27, 2022
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Journal: Targeted oncology
Published: August 02, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2021
Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma.
Journal: Gastroenterology & hepatology
Published: May 26, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 27, 2020
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 18, 2020
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 02, 2020
Last Updated: 09/26/2026